QuidelOrtho (QDEL) Cash & Equivalents (2021 - 2026)

QuidelOrtho has disclosed Cash & Equivalents across 6 years of filings, most recently posting $140.4 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $140.4 million, up 10.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $140.4 million (up 10.46% YoY), and the FY2025 annual result was $169.8 million, up 72.74% from the prior year.
• Cash & Equivalents came in at $140.4 million for Q1 2026 at QuidelOrtho, down from $169.8 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $1.3 billion in Q2 2022 to a low of $79.0 million in Q1 2024.
• The 5-year median for Cash & Equivalents is $150.8 million (2023), against an average of $271.4 million.
• Across the five-year window, Cash & Equivalents sank 77.74% in 2024 and jumped 72.74% in 2025, its largest moves.
• QuidelOrtho's Cash & Equivalents stood at $213.2 million in 2022, then plunged by 43.95% to $119.5 million in 2023, then fell by 17.74% to $98.3 million in 2024, then surged by 72.74% to $169.8 million in 2025, then dropped by 17.31% to $140.4 million in 2026.
• The last three Cash & Equivalents figures came in at $140.4 million (Q1 2026), $169.8 million (Q4 2025), and $98.1 million (Q3 2025), per Business Quant data.